TS-ONE
  • About TS-ONE ®
  • Patient Information
  • Useful Information
  • Contact

  • 1. What’s TS-ONE ®

  • 2. Approved Countries

  • 3. Scientific Information

  • 4. Administration

Phase III Studies and Guideline Recommendations*


Gastric Cancer

Colorectal Cancer

Pancreatic Cancer

Biliary Tract Cancer

Lung Cancer

Breast Cancer

Head and Neck Cancer


* In Hong Kong, TS-ONE ® is indicated for post operative adjuvant chemotherapy for locally advanced (stage II (excluding T1), IIIA or IIIB) gastric cancer 2.

Lung Cancer
  • Kubota K et al., 2015. A randomized phase III trial of oral S-1 plus cisplatin versus docetaxel plus cisplatin in Japanese patients with advanced non-small-cell lung cancer: TCOG0701 CATS trial.
    Ann Oncol., 26(7), pp.1401-1408.
  • Nokihara H. et al., 2017. Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum- based chemotherapy (East Asia S-1 Trial in Lung Cancer).
    Ann Oncol., 28(11), pp.2698-2706.
  • Okamoto I. et al.,2010. Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer: results of a west Japan oncology group study.
    J Clin Oncol., 28(36), pp.5240-5246.
  • The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV 2018.

This Site is intended for Hong Kong healthcare professionals only. Products discussed herein may have different labeling in different countries. TS-ONE® is a registered trademark of TAIHO PHARMACEUTICAL CO., LTD. and used under license. Copyright © TAIHO PHARMACEUTICAL CO., LTD. 2020 All rights reserved.